J&J-Backed Pulmocide Fills its Lungs with $92M Series C to Fund Phase 3, Ahead of Possible IPO May 27, 2021
A UK Antifungal Player with a Big Pharma Pedigree Bags Fresh Round of Cash as it Races Toward Late-Stage Trial May 27, 2021
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections March 11, 2021
In Vitro Antifungal Activity of a Novel Topical Triazole PC945 against Emerging Yeast Candida Auris August 14, 2019
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence August 14, 2019
Pulmocide Announces Nature Research Publication Showing PC945 in Combination with Standard Antifungal Treatment Causes a Synergistic Effect Against Aspergillus Fumigatus July 8, 2019
